Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts

Ocugen, Inc. has commended retinal specialists for their crucial role in advancing modifier gene therapy through clinical trials and advisory input. These experts are instrumental in developing new treatment options for severe blindness conditions that currently have limited therapies. Ocugen continues to push gene therapy innovations in collaboration with leading medical professionals, having recently accelerated efforts in modifier gene therapies and celebrated women leaders in the field.